苓姜朮甘湯エキス shortage — JP supply status & alternatives

苓姜朮甘湯エキス

—

In supply · Australia

本草苓姜朮甘湯エキス顆粒－ｍ

In supply · 🇦🇺 Australia · short in🇯🇵 JP

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	苓姜朮甘湯エキス
Brand names	本草苓姜朮甘湯エキス顆粒－ｍ
Therapeutic category	Auto-created by Ministry of Health, Labour and Welfare — Drug Supply Status scraper

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Verified timeline regulator events

🇯🇵 1 July 2026

critical reported

🇯🇵 20 June 2026

critical reported

🇯🇵 18 June 2026

critical reported

🇯🇵 10 June 2026

critical reported

🇯🇵 8 June 2026

critical reported

🇯🇵 4 June 2026

critical reported

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.